The Hidden Corruption Behind Alexion’s $700K Per Year Drug

TL;DR Alexion Pharmaceuticals charged between $500,000 and $700,000 per patient per year for its drug Soliris, a treatment for rare genetic diseases used by roughly 11,000 people worldwide. To keep that revenue flowing, the company allegedly deployed extreme sales tactics,…







